inclusion criteria: * 4.1.1 women with an initial infection diagnosis covid-19 that has been resolved, as measured by rrt pcr, who are at least 2 months after proven viral resolution. * 4.1.2 no evidence of active/recurrent covid-19 or other serious chronic illness. * 4.1.3 have significant fatigue complaints, defined as a bimodal score of 4 or greater on the fatigue questionnaire. * 4.1.4 is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration. * 4.1.5 age \>18 years and less than 65. * 4.1.6 ability to complete evaluation surveys in english. * 4.1.7 the effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. for this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; iud; abstinence) prior to study entry and for the duration of study participation. women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. * menopausal status will be established as follows: women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an fsh and estradiol measured. if the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy. * 4.1.8 ability to understand and the willingness to sign a written informed consent document. * 4.1.9 no diagnosis of clinical depression * 4.1.10 is not taking an oxaloacetate supplement.

inclusion criteria: * 4.1.1 women with an initial infection diagnosis covid-19 that has been resolved, as measured by rrt pcr, who are at least 2 months after proven viral resolution. * 4.1.2 no evidence of active/recurrent covid-19 or other serious chronic illness. * 4.1.3 have significant fatigue complaints, defined as a bimodal score of 4 or greater on the fatigue questionnaire. * 4.1.4 is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration. * 4.1.5 age \>18 years and less than 65. * 4.1.6 ability to complete evaluation surveys in english. * 4.1.7 the effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. for this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; iud; abstinence) prior to study entry and for the duration of study participation. women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. * menopausal status will be established as follows: women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an fsh and estradiol measured. if the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy. * 4.1.8 ability to understand and the willingness to sign a written informed consent document. * 4.1.9 no diagnosis of clinical depression * 4.1.10 is not taking an oxaloacetate supplement.

inclusion criteria: - 4.1.1 women with an initial infection diagnosis covid-19 that has been resolved, as measured by rrt pcr, who are at least 2 months after proven viral resolution. - 4.1.2 no evidence of active/recurrent covid-19 or other serious chronic illness. - 4.1.3 have significant fatigue complaints, defined as a bimodal score of 4 or greater on the fatigue questionnaire. - 4.1.4 is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration. - 4.1.5 age >18 years and less than 65. - 4.1.6 ability to complete evaluation surveys in english. - 4.1.7 the effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. for this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; iud; abstinence) prior to study entry and for the duration of study participation. women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. - menopausal status will be established as follows: women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an fsh and estradiol measured. if the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy. - 4.1.8 ability to understand and the willingness to sign a written informed consent document. - 4.1.9 no diagnosis of clinical depression - 4.1.10 is not taking an oxaloacetate supplement.

inclusion criteria: - 4.1.1 women with an initial infection diagnosis covid-19 that has been resolved, as measured by rrt pcr, who are at least 2 months after proven viral resolution. - 4.1.2 no evidence of active/recurrent covid-19 or other serious chronic illness. - 4.1.3 have significant fatigue complaints, defined as a bimodal score of 4 or greater on the fatigue questionnaire. - 4.1.4 is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration. - 4.1.5 age >18 years and less than 65. - 4.1.6 ability to complete evaluation surveys in english. - 4.1.7 the effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. for this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; iud; abstinence) prior to study entry and for the duration of study participation. women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. - menopausal status will be established as follows: women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an fsh and estradiol measured. if the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy. - 4.1.8 ability to understand and the willingness to sign a written informed consent document. - 4.1.9 no diagnosis of clinical depression - 4.1.10 is not taking an oxaloacetate supplement.